Cardinal Health, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cardinal Health, Inc.
While CAR-Ts have yet to trickle down into community oncology, research focused on the CAR-T patient journey also surveyed community practices on CAR-T outside the traditional academic space.
Teva has settled with the state of Rhode Island on opioid-related claims and is set to pay the state $21m in cash and provide $78.5m worth of Narcan and Suboxone. The settlement was reached just as Rhode Island was preparing to take Teva to trial.
J&J and distributors have enough participation from states and subdivisions to move forward with $26bn settlement. The deal, the second largest in US history, may provide a framework for other companies to reach similar agreements. Jury trials remain pending in several states.
2022 will be an important year for biosimilar manufacturers as the market expands into new areas like ophthalmology and insulin, and as the Humira US biosimilar entry nears in 2023.
- Contract Research, Toxicology Testing-CRO
- Medical Devices
- Home Infusion
- Hospitals, Nursing Homes, Institutions
- Pharmacy Services, PBMs
- Controlled Release
- Drug Delivery
- Other Names / Subsidiaries
- Allegiance Healthcare Corporation
- Cordis Corporation
- Innovative Therapies, naviHealth
- The Harvard Drug Group
- VIASYS Healthcare